Abstract
HAE is characterized by recurrent angioedema attacks. Lanadelumab is approved for HAE attack prevention in patients ≥12 years old (y.o.). Data across studies were integrated to evaluate the similarity of the PK/PD and E-R relationships between patients 2–<12 and ≥12 y.o. to support the dosing recommendation for patients 2–<12 y.o.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
